Adel Kardosh is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 164 publications with 2,853 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 97239
Telephone
503-494-8534Registry record last updated 5 Jun 2018.
Clinical trials
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
Sponsor: OHSU Knight Cancer Institute
- Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
Sponsor: OHSU Knight Cancer Institute
- Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- Eisai Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
37.1%Opioid Agonist15.4%Loperamide100%Part D≥22 patientsAntidiarrheal microorganisms6.4%Creon100%Part D<11 patients+ 3 more classes in this area
Nervous system
32.2%Phenothiazine17.2%Prochlorperazine Maleate100%Part D≥34 patientsOpioid Agonist7.9%Oxycodone Hcl100%Part D≥15 patients+ 1 more class in this area
Sensory organs
17.6%Corticosteroid17.6%Dexamethasone100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications
Current Problems in Cancer
2024 - Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages
bioRxiv (Cold Spring Harbor Laboratory)
2024 - Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”